The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study is to determine the response rate and safety profile of irinotecan plus epirubicin
as the second-line chemotherapy for advanced gastric cancer and fully evaluate the
feasibility and effectiveness of the regime.